David Fajgenbaum, MD, MBA, MSc’s Post

New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD

Exciting news! Researchers have made a major breakthrough in understanding IBD, which could lead to new treatments using existing drugs. Dr. James Lee from The Francis Crick Institute shared that their findings reveal "one of the very central pathways that goes wrong when people get inflammatory bowel disease." This discovery is a crucial step towards understanding and treating IBD more effectively. Ruth Wakeman at Crohn's & Colitis UK highlights this as a "step towards the possibility of a world free from Crohn’s and colitis." Our mission at Crohn's Colitis Cure is to improve care now and be instrumental in finding a cure for IBD. Join us in celebrating this important milestone! Read more: https://lnkd.in/g7yAd2pm #IBDBreakthrough #CrohnsDisease #UlcerativeColitis #MedicalResearch #CrohnsColitisCure #IBDAwareness #HealthcareAdvancements #ResearchForACure #FutureOfHealth

Chronic Venous Insufficiency Market Growth Anticipated by 2034 | Companies includes Verigraft, MediWound, TissueTech, Amniox Medical: Chronic Venous Insufficiency Market Several factors are expected to accelerate the growth of the Chronic Venous Insufficiency market during the forecast period (2023–2034). Increased awareness about available treatments, rising disease prevalence, and heightened disease awareness are key drivers. In the … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

🎯 Targeted Therapies for PsA and axSpA—Are You Ready? Join us on November 13, 2024, for a live webinar featuring Dr. Atul Deodhar, where we’ll dive into the latest clinical evidence and guidelines for treating Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA). Gain practical tools to improve your practice and patient outcomes! 🔗 https://ow.ly/Ho3t50TEyVn #OSPA2024 #Rheumatology #PsA #axSpA #VirtualLearning

(4/9) PI3Kα-Driven Vascular Malformations is the first of two programs in #geneticdisease that we unveiled today. #Vascularmalformations are a series of rare syndromes that occur due to atypical development of lymphatic and/or blood vessels, of which mutant PI3Kα is the most common driver. There are over ~170,000 patients with PI3Kα-driven vascular malformations in the U.S. We believe our mutant-selective PI3Kα inhibitor, RLY-2608, provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability for these patients. We plan to initiate clinical development in Q1 2025.

Join Clario on May 16 for an enlightening webinar that explores Parkinson’s disease endpoint data collection. Our experts will delve into topics that include: -Sensitivity of digital measures in disease progression monitoring -Efficacy and quality of life evaluations using clinical scales and patient-reported outcomes -Imaging features for biomarker-guided drug development Register now to gain invaluable insights in Parkinson's disease research: https://lnkd.in/eCN3y5jb #ParkinsonsResearch #EndpointDataCollection #Webinar

Attend #EAHAD2025 and learn about the latest EUHASS data

🚀 Revolutionizing Treatment for Hereditary Angioedema! Hereditary angioedema patients, relief is on the horizon! A groundbreaking CRISPR-based therapy, NTLA-2002, offers hope with the potential of lifelong control over this challenging condition. 🌟 In a recent trial, individuals treated with NTLA-2002 experienced a remarkable reduction in angioedema attacks, with up to 77% fewer episodes compared to placebo. Almost three-quarters of the patients receiving the higher dose remained attack-free without additional treatment! While some mild side effects were noted, the overall impact was overwhelmingly positive, paving the way for more extensive trials and a potential new chapter in treatment. With continued research, this innovative therapy could represent a major step forward in managing hereditary angioedema! 🔬✨ Read Research 👉🏻 https://lnkd.in/dRxzqhWD #research #pubmed

ELEVA’s TREATMENT FOR FABRY DISEASE Patients with #Fabry disease face several challenges with biweekly #enzymereplacementtherapy (#ERT) currently on the market. These therapies, while life-saving and critical in managing the disease, present unique obstacles: Frequent Visits: Biweekly infusions of current therapies require significant time for preparation, administration, and observation. This can disrupt personal, professional, and educational commitments. Treatment Fatigue: The biweekly nature of current ERT can lead to burnout and reduced adherence over time. Cost: These therapies are expensive, and even with insurance, co-payments or deductibles can pose a significant financial burden. In many regions, these drugs are either unavailable or prohibitively expensive. In sum, patients receiving currently available ERT for Fabry disease benefit greatly from the treatment but face significant logistical and financial challenges. #Eleva has developed a new recombinant human #alphaGalactosidase (RPV-001) for the treatment of Fabry disease. In a successful #clinicalphase1 study in patients, the compound displayed beneficial safety data. Moreover, the data indicate a possibly significantly longer dose-equivalent treatment interval, reducing the burden for the patient. Finally, the cost-of-goods are distinctly lower by expressing the molecule using #Eleva ‘s unique #moss -based #manufacturing platform (#Bryotechnology ). Meet us during the #JPMorganHealthWeek to learn about this asset and discuss possibilities to cooperate in its further development.

🔬 Detecting blood clots swiftly is crucial in healthcare. D-dimer, a protein fragment produced when blood clots dissolve, serves as a vital biomarker for identifying clot formation in the bloodstream. 💉 Introducing the RapidFor D-Dimer Rapid Test: an advanced diagnostic solution meticulously designed to provide swift and precise results. By measuring D-dimer levels accurately, this test empowers healthcare professionals to promptly diagnose and initiate treatment for thrombotic disorders, ensuring enhanced clinical efficiency and improved patient outcomes. Stay updated on the forefront of clot detection and patient care with the RapidFor D-Dimer Rapid Test. Experience the benefits of cutting-edge technology in healthcare. 🔍💉 📧 For more information on enhancing your laboratory's diagnostic capabilities, please contact us at sales@vitrosens.com. Please read the full blog: https://lnkd.in/dgBaf_vE #DDimer #DDimerRapidTestKit #RapidFor #Vitrosens #VitrosensBiotechnology #InTestWeTrust